Imed Infinity Medical-Limited Partnership (IMED) Fair Value & Analysis
Healthcare · Il · Market cap 6.2M ILA · ISIN IL0011712309
Risks
Fair value as of: Aug 28, 2026
From 1 valuation models · updated today
Share price −5.9% over the past month.
A solid business, but trading 513% above our fair value.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
What matters now
- The price sits above even our optimistic bull case (0.1785 ILA). The favourable scenario is already priced in.
- The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
- Solid but not exceptional quality (53/100) and above fair value, neither a clear bargain nor a standout compounder.
- A fairly wide model range (0.0935 ILA to 0.1785 ILA) leaves room in how you read the outcome.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 28, 2026.
How to read this chart
60‑month range 0.5340 ILA – 7.59 ILA · fair‑value band 0.0935 ILA – 0.1785 ILA · the 0.8860 ILA price screens above the 0.1445 ILA fair value. Dashed = 300-day average. As of Aug 28, 2026.
Analysis
Imed Infinity Medical-Limited Partnership (IMED) currently trades at 0.8860 ILA, while our model-based Fair Value estimate is 0.1445 ILA, implying the stock looks roughly 83.7% overvalued today. The Quality Score stands at 53/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).
Revenue grew 166.7% year over year. It earns a return on equity of -2.5%. The balance sheet holds a net cash position of 2.9M ILA. Fundamentals as of Aug 28, 2026
Our scenario range runs from 0.0935 ILA (bear case) to 0.1785 ILA (bull case); at 0.8860 ILA, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. For context, the median of 10 Healthcare peers we cover trades at -64% fair-value upside, at -84%, IMED screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 1 models by family
Notify me when IMED reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 28, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 56 · Market factors (momentum, volatility) 28
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.
About the company
Imed Infinity Medical-Limited Partnership engages in research and development and invests in projects in the medical field in Israel.
Full company description
Imed Infinity Medical-Limited Partnership engages in research and development and invests in projects in the medical field in Israel. The company's products include Genoox, a platform for gathering genetic data; biobeat medical smartmonitoring, which provides wireless patient monitoring solutions for both clinical and at-home use; Polaris Quantum Biotech, a system for the computerized design of drugs using quantum computers; and Cynerio, which focuses on ensuring patient safety and data protection by securing the connected medical device ecosystem. It also provides Theranica, which provides migraine treatment through neuromodulation; CytoReason, a computer system that performs modeling of the human body; and Nanomedic, a portable electrospinning device for the treatment and healing of complex burns and wounds. Imed Infinity Medical-Limited Partnership was incorporated in 2020 and is based in Tel Aviv-Yafo, Israel.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Imed Infinity Medical-Limited Partnership reported revenue of 41.0K ILA in FY2024 versus 75.0K ILA in FY2021, a compound −18.2%/yr. Reported net income was −147K ILA in FY2025.
IMED screens 84% overvalued. Compare with Veeva Systems Inc →
Peer Group
Health Information Services · 130 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Health Information Services median · lower = cheaper
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Health Information Services stocks, each showing price versus our Fair Value estimate (as of Aug 28, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Veeva Systems Inc VEEV | $244.91 | $91.49 | -63% |
| Pro Medicus Limited PME | A$183.71 | A$23.74 | -87% |
| BrightSpring Health Services, Inc BTSG | $59.68 | $21.31 | -64% |
| HealthEquity, Inc HQY | $104.27 | $56.63 | -46% |
| Hinge Health, Inc HNGE | $86.32 | $24.03 | -72% |
| 10x Genomics, Inc TXG | $55.63 | $17.18 | -69% |
| Waystar Holding WAY | $24.54 | $12.86 | -48% |
| XtalPi Holdings 2228 | HK$8.19 | HK$1.04 | -87% |
| Doximity, Inc DOCS | $24.74 | $25.91 | +5% |
| Privia Health Group PRVA | $21.07 | $5.26 | -75% |
Compare Imed Infinity Medical-Limited Partnership with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Discover undervalued stocks
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Imed Infinity Medical-Limited Partnership (IMED) overvalued or undervalued?
What is the fair value of IMED?
What is the quality score of IMED?
What is the net profit margin of IMED?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Watch Imed Infinity Medical-Limited Partnership in the live analysis
One click puts Imed Infinity Medical-Limited Partnership on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.